Once this molecular testing method is validated in larger multicenter studies, cell-free DNA analysis of retinoblastoma may allow physicians to precisely identify germline RB1 or MYCN mutations and prepare personalized therapy regimens and family genetic counseling. This evidence concerns the gene RB1 and retinoblastoma.